Symbols / TNGX Stock $26.33 +2.25% Tango Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TNGX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Malte Peters M.D.
Exch · Country NGM · United States
Market Cap 3.80B
Enterprise Value 3.45B
Income -101.59M
Sales 62.38M
FCF (ttm) -60.86M
Book/sh 2.55
Cash/sh 2.40
Employees 137
Insider 10d —
IPO Sep 03, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -16.46
PEG —
P/S 60.88
P/B 10.34
P/C —
EV/EBITDA -31.62
EV/Sales 55.26
Quick Ratio 15.83
Current Ratio 16.32
Debt/Eq 9.70
LT Debt/Eq —
EPS (ttm) -0.87
EPS next Y -1.60
EPS Growth —
Revenue Growth -100.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-05
ROA -19.45%
ROE -37.23%
ROIC —
Gross Margin -111.86%
Oper. Margin -178.39%
Profit Margin -162.85%
Shs Outstand 144.24M
Shs Float 68.44M
Insider Own 1.38%
Instit Own 119.87%
Short Float 28.27%
Short Ratio 12.82
Short Interest 40.25M
52W High 28.41
vs 52W High -7.32%
52W Low 1.03
vs 52W Low 2,456.31%
Beta 1.31
Impl. Vol. 3.13%
Rel Volume 0.78
Avg Volume 3.28M
Volume 2.56M
Target (mean) $23.90
Tgt Median $20.50
Tgt Low $16.00
Tgt High $40.00
# Analysts 10
Recom Strong_buy
Prev Close $25.75
Price $26.33
Change 2.25%
About

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$23.90
Mean price target
2. Current target
$26.33
Latest analyst target
3. DCF / Fair value
$-7.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$26.33
Low
$16.00
High
$40.00
Mean
$23.90

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 main Stifel Buy → Buy $40
2026-04-02 init Canaccord Genuity — → Buy $30
2026-03-11 main Mizuho Outperform → Outperform $20
2026-03-09 main Stifel Buy → Buy $24
2026-03-06 main Wedbush Outperform → Outperform $19
2026-03-06 main Guggenheim Buy → Buy $20
2026-03-06 main HC Wainwright & Co. Buy → Buy $27
2026-02-23 init Mizuho — → Outperform $19
2026-02-06 main Guggenheim Buy → Buy $18
2026-01-16 main Piper Sandler Overweight → Overweight $14
2025-12-04 init Stifel — → Buy $15
2025-11-18 init Wolfe Research — → Peer Perform —
2025-11-18 main B. Riley Securities Buy → Buy $14
2025-10-24 main Guggenheim Buy → Buy $12
2025-08-19 init Piper Sandler — → Overweight $11
2025-08-06 main Guggenheim Buy → Buy $10
2025-04-14 reit HC Wainwright & Co. Buy → Buy $13
2024-12-05 reit Cantor Fitzgerald Overweight → Overweight —
2024-11-11 main B. Riley Securities Buy → Buy $8
2024-11-08 reit HC Wainwright & Co. Buy → Buy $13
News
RSS: Latest TNGX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 CRYSTAL ADAM S Officer — 38,460 $25.00 $961,500
2026-04-15 CRYSTAL ADAM S Officer — 38,460 $5.20 $199,992
2026-04-01 CRYSTAL ADAM S Officer — 27,000 $21.20 $572,478
2026-04-01 CRYSTAL ADAM S Officer — 27,000 $5.20 $140,400
2026-03-25 CRYSTAL ADAM S Officer — 12,000 $20.11 $241,320
2026-03-25 CRYSTAL ADAM S Officer — 12,000 $5.20 $62,400
2026-03-05 CRYSTAL ADAM S Officer — 20,251 $15.00 $303,765
2026-02-25 CRYSTAL ADAM S Officer — 54,345 $12.77 $694,208
2026-02-03 BECKMAN DANIELLA Chief Financial Officer — 10,317 $12.26 $126,531
2026-02-03 WEBER BARBARA L Officer and Director — 30,519 $12.26 $374,294
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
62.38
+48.29%
42.07
+15.17%
36.53
+46.93%
24.86
Operating Revenue
62.38
+48.29%
42.07
+15.17%
36.53
+46.93%
24.86
Operating Expense
173.67
-7.46%
187.66
+24.53%
150.70
+10.87%
135.93
Research And Development
132.16
-8.17%
143.92
+24.93%
115.20
+8.77%
105.91
Selling General And Administration
41.51
-5.12%
43.75
+23.22%
35.50
+18.24%
30.02
General And Administrative Expense
41.51
-5.12%
43.75
+23.22%
35.50
+18.24%
30.02
Other Gand A
41.51
-5.12%
43.75
+23.22%
35.50
+18.24%
30.02
Total Expenses
173.67
-7.46%
187.66
+24.53%
150.70
+10.87%
135.93
Operating Income
-111.29
+23.56%
-145.59
-27.52%
-114.17
-2.79%
-111.07
Total Operating Income As Reported
-111.29
+23.56%
-145.59
-27.52%
-114.17
-2.79%
-111.07
EBITDA
-109.01
+23.82%
-143.10
-28.04%
-111.76
-2.10%
-109.46
Normalized EBITDA
-109.01
+23.82%
-143.10
-28.04%
-111.76
-2.10%
-109.46
Reconciled Depreciation
2.28
-8.72%
2.50
+3.48%
2.42
+50.19%
1.61
EBIT
-111.29
+23.56%
-145.59
-27.52%
-114.17
-2.79%
-111.07
Net Income
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Pretax Income
-101.59
+21.91%
-130.09
-28.03%
-101.61
+6.02%
-108.12
Net Non Operating Interest Income Expense
5.63
-28.64%
7.89
+19.20%
6.62
+354.60%
1.46
Net Interest Income
5.63
-28.64%
7.89
+19.20%
6.62
+354.60%
1.46
Interest Income Non Operating
5.63
-28.64%
7.89
+19.20%
6.62
+354.60%
1.46
Interest Income
5.63
-28.64%
7.89
+19.20%
6.62
+354.60%
1.46
Other Income Expense
4.07
-46.54%
7.61
+28.05%
5.94
+298.12%
1.49
Other Non Operating Income Expenses
4.07
-46.54%
7.61
+28.05%
5.94
+298.12%
1.49
Tax Provision
0.00
-98.08%
0.21
+55.22%
0.13
+148.15%
0.05
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Net Income From Continuing Operation Net Minority Interest
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Net Income From Continuing And Discontinued Operation
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Net Income Continuous Operations
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Normalized Income
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Net Income Common Stockholders
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Diluted EPS
—
-1.19
-10.19%
-1.08
+12.20%
-1.23
Basic EPS
—
-1.19
-10.19%
-1.08
+12.20%
-1.23
Basic Average Shares
—
109.23
+15.50%
94.57
+7.69%
87.82
Diluted Average Shares
—
109.23
+15.50%
94.57
+7.69%
87.82
Diluted NI Availto Com Stockholders
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
398.69
+25.97%
316.49
-21.38%
402.57
-7.77%
436.47
Current Assets
353.76
+32.82%
266.34
-23.14%
346.54
-7.66%
375.27
Cash Cash Equivalents And Short Term Investments
343.14
+33.04%
257.92
-23.44%
336.88
-7.99%
366.13
Cash And Cash Equivalents
112.28
+61.48%
69.53
+4.74%
66.39
+10.70%
59.97
Other Short Term Investments
230.86
+22.55%
188.39
-30.36%
270.50
-11.65%
306.17
Receivables
—
—
0.00
-100.00%
2.00
Accounts Receivable
—
—
0.00
-100.00%
2.00
Prepaid Assets
—
—
—
—
Restricted Cash
0.43
0.00
-100.00%
0.86
+50.97%
0.57
Other Current Assets
10.19
+20.94%
8.43
-4.22%
8.80
+33.86%
6.57
Total Non Current Assets
44.93
-10.40%
50.15
-10.49%
56.03
-8.45%
61.20
Net PPE
42.49
-10.69%
47.58
-10.93%
53.42
-7.54%
57.77
Gross PPE
53.03
-5.20%
55.94
-5.83%
59.41
-3.33%
61.45
Accumulated Depreciation
-10.54
-26.01%
-8.36
-39.64%
-5.99
-62.70%
-3.68
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.75
+5.33%
4.51
+6.95%
4.21
+3.82%
4.06
Construction In Progress
0.00
-100.00%
0.15
+300.00%
0.04
+375.00%
0.01
Other Properties
44.56
-7.96%
48.41
-7.43%
52.30
-4.23%
54.61
Leases
3.72
+29.72%
2.87
+0.46%
2.86
+2.84%
2.78
Other Non Current Assets
2.44
-5.02%
2.57
-1.61%
2.61
-23.77%
3.43
Total Liabilities Net Minority Interest
52.51
-55.11%
116.97
-21.73%
149.46
-20.07%
186.99
Current Liabilities
21.68
-43.20%
38.17
-16.91%
45.94
-17.30%
55.55
Payables And Accrued Expenses
17.65
+7.88%
16.36
-3.17%
16.90
-18.43%
20.72
Payables
1.18
-26.17%
1.60
-42.51%
2.79
-37.95%
4.49
Accounts Payable
1.18
-26.17%
1.60
-42.51%
2.79
-37.46%
4.45
Current Accrued Expenses
16.47
+11.57%
14.76
+4.59%
14.11
-13.03%
16.23
Pensionand Other Post Retirement Benefit Plans Current
—
—
—
—
Total Tax Payable
—
—
0.00
-100.00%
0.04
Income Tax Payable
—
—
0.00
-100.00%
0.04
Current Debt And Capital Lease Obligation
2.74
+11.57%
2.45
+17.87%
2.08
+17.63%
1.77
Current Capital Lease Obligation
2.74
+11.57%
2.45
+17.87%
2.08
+17.63%
1.77
Current Deferred Liabilities
0.00
-100.00%
17.62
-31.37%
25.67
-19.26%
31.79
Current Deferred Revenue
0.00
-100.00%
17.62
-31.37%
25.67
-19.26%
31.79
Other Current Liabilities
1.29
-25.71%
1.74
+34.81%
1.29
+1.58%
1.27
Total Non Current Liabilities Net Minority Interest
30.83
-60.88%
78.81
-23.88%
103.52
-21.25%
131.45
Long Term Debt And Capital Lease Obligation
30.83
-9.42%
34.04
-7.60%
36.84
-6.41%
39.36
Long Term Capital Lease Obligation
30.83
-9.42%
34.04
-7.60%
36.84
-6.41%
39.36
Non Current Deferred Liabilities
0.00
-100.00%
44.77
-32.87%
66.68
-27.59%
92.09
Non Current Deferred Revenue
0.00
-100.00%
44.77
-32.87%
66.68
-27.59%
92.09
Preferred Securities Outside Stock Equity
0.00
0.00
0.00
0.00
Stockholders Equity
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Common Stock Equity
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Capital Stock
0.14
+25.93%
0.11
+5.88%
0.10
+15.91%
0.09
Common Stock
0.14
+25.93%
0.11
+5.88%
0.10
+15.91%
0.09
Share Issued
135.94
+26.19%
107.73
+5.41%
102.20
+15.90%
88.18
Ordinary Shares Number
135.94
+26.19%
107.73
+5.41%
102.20
+15.90%
88.18
Additional Paid In Capital
948.97
+35.45%
700.63
+12.27%
624.08
+19.42%
522.61
Retained Earnings
-603.15
-20.26%
-501.56
-35.10%
-371.26
-37.75%
-269.51
Gains Losses Not Affecting Retained Earnings
0.22
-33.33%
0.34
+80.65%
0.19
+105.02%
-3.71
Other Equity Adjustments
0.22
-33.33%
0.34
+80.65%
0.19
+105.02%
-3.71
Total Equity Gross Minority Interest
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Total Capitalization
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Working Capital
332.08
+45.54%
228.17
-24.09%
300.60
-5.98%
319.73
Invested Capital
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Total Debt
33.57
-8.01%
36.49
-6.24%
38.92
-5.38%
41.13
Capital Lease Obligations
33.57
-8.01%
36.49
-6.24%
38.92
-5.38%
41.13
Net Tangible Assets
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Tangible Book Value
346.18
+73.51%
199.52
-21.17%
253.11
+1.46%
249.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-138.89
-5.62%
-131.50
-11.46%
-117.98
-8.16%
-109.08
Cash Flow From Continuing Operating Activities
-138.89
-5.62%
-131.50
-11.46%
-117.98
-8.16%
-109.08
Net Income From Continuing Operations
-101.59
+22.03%
-130.30
-28.07%
-101.74
+5.95%
-108.18
Depreciation Amortization Depletion
2.28
-8.72%
2.50
+3.48%
2.42
+50.19%
1.61
Depreciation
2.28
-8.72%
2.50
+3.48%
2.42
+50.19%
1.61
Depreciation And Amortization
2.28
-8.72%
2.50
+3.48%
2.42
+50.19%
1.61
Other Non Cash Items
3.88
+3.08%
3.77
+3.86%
3.63
+107.20%
1.75
Stock Based Compensation
26.43
-8.54%
28.90
+51.46%
19.08
+34.08%
14.23
Change In Working Capital
-67.20
-111.68%
-31.75
+16.38%
-37.97
-105.30%
-18.49
Change In Receivables
0.00
0.00
-100.00%
2.00
0.00
Changes In Account Receivables
0.00
0.00
-100.00%
2.00
0.00
Change In Prepaid Assets
-1.76
-576.49%
0.37
+116.63%
-2.23
-8.22%
-2.06
Change In Payables And Accrued Expense
0.28
+658.00%
-0.05
+98.66%
-3.73
-142.79%
8.73
Change In Accrued Expense
1.10
-2.65%
1.13
+155.89%
-2.03
-126.60%
7.63
Change In Payable
-0.82
+30.32%
-1.18
+30.56%
-1.71
-255.42%
1.10
Change In Account Payable
-0.82
+30.32%
-1.18
+30.56%
-1.71
-255.42%
1.10
Change In Other Working Capital
-62.38
-108.16%
-29.97
+4.94%
-31.53
-86.99%
-16.86
Change In Other Current Assets
-0.30
-795.35%
0.04
+204.88%
-0.04
+99.59%
-10.00
Change In Other Current Liabilities
-3.03
-41.68%
-2.14
+12.26%
-2.44
-243.47%
1.70
Investing Cash Flow
-40.87
-147.45%
86.13
+107.90%
41.43
+56.92%
26.40
Cash Flow From Continuing Investing Activities
-40.87
-147.45%
86.13
+107.90%
41.43
+56.92%
26.40
Net PPE Purchase And Sale
-1.05
-38.99%
-0.75
+50.59%
-1.53
+80.16%
-7.69
Purchase Of PPE
-1.05
-38.99%
-0.75
+50.59%
-1.53
+80.16%
-7.69
Capital Expenditure
-1.05
-38.99%
-0.75
+50.59%
-1.53
+80.16%
-7.69
Net Investment Purchase And Sale
-39.82
-145.83%
86.88
+102.27%
42.95
+25.99%
34.09
Purchase Of Investment
-264.46
-9.78%
-240.89
+22.44%
-310.57
-48.95%
-208.50
Sale Of Investment
224.64
-31.46%
327.77
-7.29%
353.53
+45.73%
242.59
Financing Cash Flow
222.50
+366.81%
47.66
-42.16%
82.41
+5002.54%
1.61
Cash Flow From Continuing Financing Activities
222.50
+366.81%
47.66
-42.16%
82.41
+5002.54%
1.61
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
212.40
+409.07%
41.72
-47.86%
80.02
0.00
Proceeds From Stock Option Exercised
10.14
+70.61%
5.94
+206.08%
1.94
+19.59%
1.62
Net Other Financing Charges
-0.04
—
0.45
+5700.00%
-0.01
Changes In Cash
42.75
+1767.58%
2.29
-60.87%
5.85
+107.22%
-81.07
Beginning Cash Position
72.10
+3.28%
69.81
+9.15%
63.96
-55.90%
145.02
End Cash Position
114.85
+59.29%
72.10
+3.28%
69.81
+9.15%
63.96
Free Cash Flow
-139.93
-5.81%
-132.25
-10.67%
-119.51
-2.34%
-116.77
Amortization Of Securities
-2.69
+41.78%
-4.62
-36.03%
-3.39
0.00
Common Stock Issuance
212.40
+409.07%
41.72
-47.86%
80.02
0.00
Issuance Of Capital Stock
212.40
+409.07%
41.72
-47.86%
80.02
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category